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Abstract
Background: Low-normal thyroid function within the euthyroid range may contribute to increased atherosclerosis
susceptibility. The leptin/adiponectin (L/A) ratio is associated with cardiovascular disease and reflects adipose tissue
dysfunction. Relationships of the L/A ratio with low-normal thyroid function are unknown.
Methods: Relationships of thyroid stimulating hormone (TSH) and free thyroxine (free T4) with leptin, adiponectin
and the L/A ratio in euthyroid subjects were documented in 67 fasting subjects with metabolic syndrome (Mets)
and 86 euthyroid subjects without MetS (TSH and free T4 levels within the institutional reference range).
Results: Neither plasma leptin nor adiponectin was significantly correlated with TSH or free T4 in subjects with and
without MetS. In the whole group, high sensitivity C-reactive protein (hs-CRP) was positively correlated with the L/A
ratio (r = 0.485, P < 0.001). Notably, the L/A ratio was positively correlated with TSH in subjects with MetS (r = 0.252,
P = 0.040) but not in subjects without MetS (r = −0.068, P = 0.54; interaction term, P = 0.027). In MetS subjects, the
L/A ratio remained positively related with TSH after adjustment for age, sex, diabetes status, hs-CRP and the use of
antihypertensive and glucose lowering medication (β = 0.283, P = 0.018), as well as after adjustment for individual
MetS components (β = 0.294, P = 0.020).
Conclusions: In the context of MetS, a higher TSH within the euthyroid range confers an increased L/A ratio, a
proposed marker of atherosclerosis susceptibility and adipocyte dysfunction.
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Background
The concept is emerging that low-normal thyroid func-
tion, as inferred from a higher thyroid stimulating
hormone (TSH) or a lower free thyroxine (free T4)
within the euthyroid range, may adversely impact several
health issues including the development of cardiovascu-
lar disorders [1, 2]. In line with this concept, low-normal
thyroid function is associated with a greater increased
intima media thickness (cIMT), an established bio-
marker of subclinical atherosclerosis [3, 4]. Furthermore,
low-normal thyroid function is associated with increased
coronary artery calcification [5] and progression thereof
[6], although an association of a high-normal TSH level
with increased coronary heart disease risk has been vari-
ably reported [7, 8].
Several factors are likely to contribute to the associ-
ation of (subclinical) atherosclerosis with low-normal
function. Low-normal thyroid function relates to higher
plasma levels of total cholesterol and atherogenic apoli-
poprotein B-containing lipoproteins [9], and contributes
to enhanced cholesteryl ester transfer from HDL to
triglyceride-rich lipoproteins, a pro-atherogenic process
[10, 11]. Low-normal thyroid function conveys
changes in high density lipoprotein (HDL) anti-
oxidative function as well, which conceivably con-
tribute to impaired oxidative stress defense [12].
Interestingly, thyroid function status affects circulat-
ing levels of leptin and adiponectin, adipokines
which exert pro- and anti-atherogenic properties, re-
spectively [13–15]. Thus, leptin has been reported to
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decrease and adiponectin to increase after levothyr-
oxine supplementation in subclinical hypothyroidism
[16]. These findings provide a rationale to hypothesize
that the plasma leptin/adiponectin (L/A) ratio is higher in
subjects with low-normal thyroid function. Of note, the L/
A ratio may represent a preferential marker compared to
leptin and adiponectin alone in predicting incident cardio-
vascular disease [17, 18]. The L/A ratio is also considered
to represent a biomarker of adipocyte dysfunction [19].
Higher plasma leptin and lower adiponectin levels are well
known features of the metabolic syndrome (MetS) [20].
As a result, the L/A ratio is elevated in MetS [21–23],
which supports the potential clinical relevance to deter-
mine relationships of low-normal thyroid function with
the L/A ratio in subjects with MetS.
We initiated the present study to determine possible
relationships of plasma leptin, adiponectin and the L/A




The study protocol was approved by the medical ethics
committee of the University Medical Center Groningen,
the Netherlands, approved the study. Written informed
consent was obtained from the participants, who were
aged > 18 years. Type 2 Diabetes Mellitus (T2DM) and
non-diabetic subjects were approached by advertisement
in local newspapers. T2DM had been diagnosed previ-
ously by primary care physicians applying a fasting
plasma glucose ≥ 7.0 mmol/l and/or non-fasting plasma
glucose ≥11.1 mmol/l as diagnostic criteria. MetS was
defined according to NCEP-ATP III criteria [24].
Three or more of the following criteria were required
for categorization of subjects with MetS: waist cir-
cumference >102 cm for men and >88 cm for
women; hypertension (blood pressure ≥ 130/85 mmHg
or use of antihypertensive drugs); fasting plasma tri-
glycerides ≥ 1.7 mmol/l; HDL cholesterol < 1.0 mmol/l
for men and <1.3 mmol/l for women; fasting glu-
cose ≥ 5.6 mmol/l.
Serum TSH and free T4 levels had to be within the
institutional reference range, and anti-thyroid peroxid-
ase (anti-TPO) and anti-thyroglobulin (anti-Tg) auto-
antibodies had to be absent (see below).
Subjects with a history of cardiovascular disease
(CVD), chronic kidney disease (estimated glomerular fil-
tration rate < 60 ml/min/1.73 m2 or micro/macroalbumi-
nuria), liver disorders (serum transaminase levels >two
times the upper reference limit), as well as current
smokers, subjects who used lipid lowering drugs or insu-
lin were also excluded from participation as were preg-
nant women. The use of anti-hypertensive medication
and oral contraceptives was allowed.
Physical examination did not reveal pulmonary or car-
diac abnormalities. Body mass index (BMI) was calcu-
lated as weight (kg) divided by height (m) squared.
Blood pressure was measured after 15 min of rest at the
left arm using a sphygmomanometer. The participants
were evaluated between 0800 and 1000 h after an
overnight fast.
Laboratory analyses
Serum and EDTA-anticoagulated plasma samples, pre-
pared by centrifugation at 1400 g for 15 min at 4 °C,
were stored at −80 °C until analysis. Plasma glucose was
measured shortly after blood collection.
Serum TSH (sandwich principle; Roche Diagnostics
GmbH., Mannheim, Germany, cat. no. 117314591; refer-
ence range 0.5–4.0 mU/l) and free T4 (competition
principle; Roche Diagnostics GmbH., Mannheim Germany,
cat. no. 11731297; reference range 11.0–19.5 pmol/l) were
measured with a electrochemiluminescence immunoassay
on a Modular Analytics immunoassay analyzer. Anti-TPO
and anti-Tg) auto-antibodies were measured with enzyme-
linked immunoassays (ImmunoCap cat nos. 14-4508-35
and 14-4507-35, respectively; Phadia, Freiburg, Germany),
and were considered to be positive using cut-off values pro-
vided by the supplier (anti-TPO antibodies > 60 IU/ml and
anti-Tg antibodies > 289 IU/ml).
Plasma leptin and total adiponectin were assayed using
commercially available assays (Luminex xMAP technol-
ogy; Linco Research Inc., St Charles, MO, USA; Linco-
plex panel A cat. no. HADK1-61 K-A and panel B cat.
no. HADK2-61 K-B) [25]. All intra-assay and inter-assay
coefficients of variation were <6 and <8%. High sensi-
tivity C-reactive protein (hs-CRP) was determined was
by nephelometry (BNII N; Dade Behring, Marburg
Germany) [17].
Plasma total cholesterol and triglycerides were assayed
by routine enzymatic methods (Roche/Hitachi cat nos
11875540 and 11876023, respectively; Roche Diagnostics
GmbH, Mannheim, Germany). HDL cholesterol was
measured with a homogeneous enzymatic colorimetric
test (Roche/Hitachi, cat no 04713214; Roche Diagnostics
GmbH, Mannheim, Germany). Non-HDL cholesterol
was calculated as the difference between total cholesterol
and HDL cholesterol. Glucose was measured on an
APEC glucose analyzer (APEC Inc., Danvers, MA, USA).
Statistical analysis
SPSS 22 (version 22.0, SPSS Inc., Chicago, IL, USA) was
used for data analysis. Data are expressed as mean ± SD,
median (interquartile ranges) or in numbers. Differences
between people with and without MetS were determined
by unpaired T-tests or Chi-square tests. Because of
skewed distribution, triglycerides, hs-CRP, leptin, adipo-
nectin and the L/A ratio were logarithmically transformed
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to compare between-group differences, and to perform
correlation analyses.
Univariate relationships were calculated using Pearson
correlation coefficients. Multivariable linear regression
analyses were carried out to disclose the independent re-
lationships of the L/A ratio with thyroid function param-
eters. To determine whether the relationships of thyroid
function parameters with the L/A ratio were different
between subjects with and without MetS, interaction
terms were calculated as the product term between
the thyroid function variable of interest and the pres-
ence of MetS. Two-sided P-values < 0.05 indicated
statistical significance.
Results
We included 67 subjects with MetS and 86 subjects
without MetS (Table 1). Forty nine subjects with MetS
and 24 subjects without MetS were diagnosed with
T2DM (P < 0.001). Twenty three subjects with MetS
and seven subjects without MetS were taken anti-
hypertensive drugs (mostly angiotensin-converting en-
zyme inhibitors, angiotensin II receptor antagonists
and diuretics, alone or in combination) (P < 0.001).
Metformin and sulfonylurea were used, either alone
or in combination, by 28 and 27 subjects with MetS,
respectively. Of the subjects without MetS, 10 used
metformin and 12 used sulfonylurea. Other glucose
lowering drugs were not used. Estrogens were taken
by two post-menopausal woman with MetS and by
one pre-menopausal woman without MetS.
Age, sex distribution, TSH and free T4 levels were not
significantly different between subjects with and without
MetS (Table 1). Blood pressure, BMI, waist, plasma glu-
cose and triglycerides were expectedly higher, whereas
HDL cholesterol was lower in MetS subjects. Total chol-
esterol and non-HDL cholesterol were not significantly
different between the groups. Plasma hs-CRP was ele-
vated in MetS subjects. Furthermore, leptin was in-
creased and adopinectin was decreased in MetS subjects
(Table 1). As a result, the L/A ratio was approximately
three-fold higher in MetS subjects.
In the whole group, hs-CRP was correlated positively
with leptin (r = 0.435, P < 0.001) and inversely with adi-
ponectin in univariate analysis (r = −0.289, P < 0.001).
Consequently, hsCRP was correlated positively with the
L/A ratio (r = 0.485, P < 0.001). In the whole group, nei-
ther plasma leptin nor adiponectin or the L/A ratio were
significantly correlated with TSH or with and free T4
(P > 0.40 for all; data not shown). Furthermore, neither
plasma leptin nor adiponectin were significantly corre-
lated with TSH and free T4 in subjects with or without
MetS (Table 2). However, the L/A ratio was positively
correlated with TSH in MetS subjects, contrasting the
lack of such a relationship in subjects without MetS
(Table 3; Fig. 1). Indeed, the relationship of the L/A ratio
with TSH was different between subjects with and with-
out MetS (interaction term for between group difference:
β = 0.201, P = 0.027). The positive relation of the L/A
ratio with TSH was also present in MetS subjects who
did not use antihypertensive drugs (n = 43; r = 0.329,
P = 0.034) or metformin (n = 39; r = 0.285, P = 0.070),
again without such relationships being found in
subjects without MetS (n = 79; r = −0.026, P = 0.82 and
n = 76, r = −0.047, P = 0.69, respectively).
Multivariable linear regression analysis demonstrated
that the positive relationship of the L/A ratio with TSH
in MetS subjects remained present after adjustment for
age, sex, diabetes status and the use of antihypertensive
and glucose lowering medication (Table 3A). No such
relationship was found in subjects without MetS
(Table 3B). In alternative analysis, the L/A ratio was also
positively related to TSH in MetS subjects when taking
the individual MetS components into account and thus
being associated with TSH independent of an enlarged
waist (Table 4A). Additionally, the L/A ratio was posi-
tively related to an enlarged waist in subjects without
Table 1 Clinical characteristics, glucose, lipids, leptin,
adiponectin, the leptin/adionectin (L/A) ratio and thyroid
function parameters in 67 subjects with metabolic syndrome






Age (years) 58 ± 9 56 ± 9 0.10
Sex (men/women) 40/27 52/34 0.92
Systolic blood pressure
(mm Hg)
144 ± 18 131 ± 20 <0.001
Diastolic blood pressure
(mm Hg)
89 ± 9 81 ± 10 <0.001
BMI (kg/m2) 29.8 ± 4.4 25.1 ± 3.3 <0.001
Waist (cm) 105 ± 12 87 ± 11 <0.001
Glucose (mmol/l) 8.6 ± 2.7 6.2 ± 1.4 <0.001
Total cholesterol (mmol/l) 5.54 ± 0.97 5.62 ± 0.97 0.60
Non-HDL cholestrerol
(mmol/l)
4.38 ± 0.98 4.07 ± 1.05 0.068
HDL cholesterol (mmol/l) 1.16 ± 0.34 1.55 ± 0.38 <0.001
Triglycerides (mmol/l) 1.96 (1.70-2.52) 1.15 (0.85-1.55) <0.001
hs-CRP (mg/l) 2.03 (1.26-4.22) 1.02 (0.48-2.25) <0.001
Leptin (μg/l) 11.5 (5.5-31.9) 4.8 (3.0-11.6) <0.001
Adiponectin (mg/l) 14.7 (9.2-26.8) 18.2 (14.2-38.8) <0.001
L/A ratio (μg/mg) 0.83 (0.37-1.85) 0.23 (0.12-0.62) <0.001
TSH (mU/l) 1.55 ± 0.70 1.66 ± 0.68 0.37
Free T4 (pmol/l) 13.9 ± 1.59 13.8 ± 1.47 0.82
Data in mean ± SD or in median (interquartile range). BMI body mass index, hs-
CRP high sensitivity C-reactive protein, TSH thyroid stimulating hormone, free
T4 free thyroxine. Logarithmically transformed values of triglycerides, hs-CRP,
leptin, adiponectin and the L/A ratio are used for statistical comparisons
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MetS (Table 4A and 4B). In the whole group, the L/A
ratio was independently associated with female sex (β =
0.338, P < 0.001), hs-CRP (β = 0.262, P < 0.001) and an
enlarged with waist (β = 0.204, P = 0.005) without an in-
dependent association with TSH (β = 0.079, P = 0.214;
data not shown).
Discussion
This study reveals to our knowledge for the first time
that the plasma L/A ratio is positively related to a higher
TSH level in euthyroid subjects with MetS but not in
subjects without MetS. This relationship in MetS sub-
jects remained present when taking relevant covariates
into account, including the presence of diabetes, hs-CRP
and the use of antihypertensive and oral glucose lower-
ing drugs, and was also present in analysis in which we
adjusted for individual MetS components, including an
enlarged waist circumference. The current results, there-
fore, suggest that the L/A ratio, an alleged predictor of
cardiovascular disease and biomarker of adipocyte dys-
function [17, 19] associates with low-normal thyroid
Table 2 Univariate relationships of leptin, adiponectin and the
leptin/adiponectin (L/A) ratio with thyroid stimulating hormone
(TSH) and free thyroxine (free T4) in 67 subjects with metabolic





TSH free T4 TSH free T4
Leptin 0.168 0.020 −0.013 −0.113
Adiponectin −0.090 −0.046 0.154 0.056
L/A ratio 0.252* 0.031 −0.068 −0.106
Pearson correlation coefficients are shown. Logarithmically transformed values
of leptin, adiponectin, the L/A ratio are used for statistical
comparisons. *P = 0.04
Table 3 Multivariable linear regression analysis demonstrating the
relationship of the leptin/adiponectin (L/A) ratio with thyroid
stimulating hormone (TSH), age, sex and diabetes status and high
sensitivity C-reactive protein (hs-CRP) in 67 subjects with metabolic
syndrome (MetS; A) and in 86 subjects without MetS (B)
L/A ratio
β P-value
A MetS (n = 67)
Age −0.130 0.25




B No MetS (n = 86)
Age −0.076 0.39




T2DM: type 2 diabetes mellitus; β: standardized regression coefficient. The L/A
ratio and hs-CRP are logarithmically transformed. Models are additionally adjusted
for the use of antihypertensive medication, sulfonylurea and metformin
Fig. 1 Relationship of the leptin/adionectin (L/A) ratio with thyroid
stimulating hormone (TSH in 67 subjects with metabolic syndrome
(MetS) (a: r = 0.252, P = 0.040) and 86 subjects without MetS
(b: r = −0.068, P = 0.54). The L/A ratio is logarithmically transformed
Table 4 Multivariable linear regression analysis demonstrating the
relationship of the leptin/adiponectin (L/A) ratio with thyroid
stimulating hormone (TSH), age, sex, metabolic syndrome (MetS)
components and high sensitivity C-reactive protein (hs-CRP) in 67
subjects with MetS (A) and in 86 subjects without MetS (B)
L/A ratio P-value
β
A MetS (n = 67)
Age −0.154 0.19
Sex (women vs. men) 0.214 0.082
Elevated glucose 0.053 0.69
Hypertension 0.138 0.25
Enlarged waist 0.201 0.12
Elevated triglycerides −0.064 0.61
Low HDL cholesterol 0.172 0.17
hs-CRP 0.090 0.47
TSH 0.294 0.020
B No MetS (n = 86)
Age −0.028 0.76
Sex (women vs. men) 0.53 <0.001
Elevated glucose 0.097 0.31
Hypertension 0.090 0.38
Enlarged waist 0.310 <0.001
Elevated triglycerides 0.177 0.047
Low HDL cholesterol 0.072 0.38
hs-CRP 0.299 <0.001
TSH −0.060 0.48
HDL high density lipoproteins, β standardized regression coefficient. The L/A
ratio and hs-CRP are logarithmically transformed. Models are additionally
adjusted for the use of sulfonylurea and metformin
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function. Altogether, the present findings add to accu-
mulating evidence which underscores the possibility that
low-normal thyroid function may confer increased ath-
erosclerosis susceptibility [1, 2, 9].
We enrolled strictly euthyroid subjects, as inferred
from TSH and free T4 levels within the institutional ref-
erence range. With this selection criterion, TSH and free
T4 were similar in subjects with MetS compared to sub-
jects without MetS. This entirely agrees with our previ-
ous findings in a small group of non-diabetic subjects
[26], although mild thyroid function changes in MetS
have been documented in another study [9]. Leptin and
adiponectin play an important role in obesity-associated
metabolic risk by modulating inflammatory processes
and affecting insulin sensitivity [19, 20, 27]. In agree-
ment, we found that the L/A ratio was positively related
to hs-CRP in univariate analysis. Given the associations
of plasma leptin and adiponectin with (central) obesity,
the strong elevations in the L/A ratio in MetS subjects
as demonstrated here is not surprising [21–23]. Accord-
ingly, waist circumference predicted the L/A ratio in the
present study, even independent of hyperglycemia and
other MetS components. We consider this finding re-
assuring because a considerable number of participants
had been diagnosed with type 2 diabetes, making that
the number subjects without diabetes was too low to
allow for meaningful subgroup analysis.
Clinical observations showing that plasma leptin de-
creases whereas adiponectin increases after levothyroxine
substitution in subjects with subclinical hypothyroidism
[16] prompted us to delineate the relationship of the L/A
ratio with low-normal thyroid function. In concert with
these human findings [16], thyroid hormone upregulates
adiponectin gene expression in rat adipose tissue [28]. In
contrast, leptin gene expression in rat epididymal fat is
downregulated after experimental hyperthyroidism, al-
though lower circulating leptin levels in response to high
thyroid hormone exposure are at least in part attributable
to a decrease in body fat [29]. It remains to be more pre-
cisely determined why there was only a relation of the L/A
ratio with TSH in the MetS subjects. In comparison, the
relationship with low-normal thyroid function with other
pro-atherogenic biomarkers have been demonstrated pre-
viously to be particularly evident in diabetic or MetS sub-
jects [2, 9, 10]. Our present observation that this
relationship remained present after adjustment for waist
circumference would be consistent with a contribution of
thyroid function status on this ratio.
A number of other limitations and methodological as-
pects of our study need to be discussed. First, we per-
formed a cross-sectional study, making that cause-effect
relationships cannot be established with certainty. How-
ever, we are not aware of published data indicating that
the leptin or adiponectin directly affect thyroid hormone
regulation. Second, we relied on a single set of thyroid
function parameters. In this regard it is noteworthy that
each individual probably has a narrow set-point of thy-
roid function status, underscoring the pathophysiological
relevance of once measured thyroid function status [30].
Third, circulating adiponectin increases in response to
angiotensin II, making that an effect of the antihyperten-
sive medication used cannot by excluded [31]. Fourth,
metformin lowers of the TSH level in hypothyroid sub-
jects and thus could alter the set-point of the pituitary-
thyroid axis [32, 33]. Notably, metformin treatment does
not elicit TSH changes in euthyroid subjects [33, 34].
For these reasons, we adjusted for the use of antihy-
pertensive and glucose lowering drugs in multivariable
regression analysis, confirming the independent rela-
tion of the L/A ratio with TSH in MetS. In addition,
the positive relation of the L/A ratio with TSH in
MetS was also present after exclusion of subjects tak-
ing antihypertensive medication or metformin, indi-
cating that the use of these medications did not
confound the interpretation of our data.
The interest for a neutraceutical approach to improve
the cardiometabolic risk profile besides well-established
pharmacological treatment modalities is growing [35]. In
this respect it is noteworthy that a combination of sev-
eral compounds including red yeast rice extract, berber-
ine, policosanol, astaxanthin, coenzyme Q10 and folic
acid has been shown to reduce the L/A ratio besides low
density lipoprotein (LDL) cholesterol lowering [36].
Given the elevated L/A ratio in MetS, additional studies
with respect to a neutraceutical approach to ameliorate
pro-atherogenic biomarkers appear to be warranted.
Conclusions
A higher TSH level within the euthyroid range confers
an increased L/A ratio in MetS subjects, which is likely
to contribute to an adverse cardiometabolic profile in
this patient category.
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